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Malaria Vaccine Trial Results Are Negative, but Important
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Supervised Treatment 
Interruptions Fail to 
Control HIV-1 Viremia
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Highly active antiretroviral therapy 
(HAART) for the treatment of individuals 
infected by HIV-1 is limited by high 
costs, drug resistance, and drug-related 
toxicities. This has led researchers to 
investigate new treatment options, 
including ways to boost immune 
responses to better control HIV. One such 
approach has been termed supervised 
treatment interruption (STI)—in which 
HAART is intermittently stopped once 
viral load has been reduced to a low 
level, in order to boost natural immunity 
by brief exposure to virus. The goal is to 
allow for the eventual discontinuation of 
drug treatment. 
Preliminary evidence, published by 
Bruce Walker and his colleagues from 
Harvard Medical School in Nature in 
2000, suggested that this approach 
worked in persons treated in the earliest 
stages of acute HIV infection. HIV-1 
viral loads in newly infected patients 
remained suppressed for a median of six 
months after therapy had been stopped. 
However, a follow up paper, published 
this month in PLoS Medicine by the same 
research group, shows that the viral load 
rebounded in eight of the 14 patients by 
one year.
“The ﬁ  ndings are very straightforward 
and very important,” comments Danny 
Douek from the Vaccine Research Center, 
National Institutes of Health, United 
States, who was not involved in the study. 
“In almost every case, virus rebounded 
and no clinical beneﬁ  t from the 
interruption could be determined.” 
Walker’s team ﬁ  rst considered the 
possibility of STI in 1997 after they 
demonstrated that HAART given to 
patients recently infected with HIV 
A malaria vaccine called ME-TRAP, which targets the pre-
erythrocytic stage of the disease, was not effective at reducing 
natural infection rates in semi-immune African adults, according 
to the report of a randomized controlled trial published this 
month in PLoS Medicine.  “This ﬁ  rst ﬁ  eld efﬁ  cacy trial was an 
important milestone in the progression of new recombinant 
vectored vaccines to deployable products,” says Adrian Hill 
(University of Oxford, United Kingdom), the lead investigator of 
the study. “The safety proﬁ  le was excellent and the efﬁ  cacy data 
provide a ﬁ  rst indication of the levels of cellular immunogenicity 
that will be required for preventing infection,” he says. 
Hill and his co-workers used a heterologous prime–boost 
vaccination technique. They gave the volunteers two vaccines—a 
DNA priming vaccine followed by a modiﬁ  ed vaccinia virus 
Ankara (MVA) that acted as a booster. The DNA and MVA vaccines 
both had the same insert coding for thrombospondin-related 
adhesion protein (TRAP; a pre-erythrocytic antigen) and a string 
of T cell epitopes (called ME for “multiple epitopes”). 
Hill’s team had previously shown that ME-TRAP vaccines given 
in prime–boost sequence could induce large T cell responses in 
healthy volunteers from the UK and could delay parasitemia in 
a sporozoite challenge test (Nat Med 9: 729–735). The next step 
was to do a randomized controlled trial in Gambia to determine 
whether this vaccination strategy could provide protection 
against natural Plasmodium falciparum infection. 
The researchers recruited volunteers from 13 Gambian villages 
that were close to the alluvial ﬂ  ood plain and so were at high 
risk of developing malaria. They randomly assigned the 372 
volunteers to receive either two doses of the DNA ME-TRAP 
vaccine followed by a single dose of MVA ME-TRAP, or three 
doses of rabies vaccine. This three-dose schedule is similar to 
the one used by the World Health Organization/United Nations 
Children’s Fund Expanded Program on Immunization. Two weeks 
before the third dose was given, all the volunteers received 
antimalarial drugs to clear blood-stage P. falciparum infections.
The time to ﬁ  rst infection, the primary end point of the study, 
was similar in the two groups, with an estimated vaccine efﬁ  cacy 
of only 10%. However, the effector T cell response to the TRAP 
antigen T9/96, measured one week after the third vaccination, 
was 80 times higher in the DNA/MVA vaccine group than in the 
rabies vaccine group. 
“It is absolutely crucial that results like these are published, 
since the failures, as well as the successes, need to be 
documented if we are to move towards rational strategies for 
optimizing malaria vaccines,” says Tom Smith from the Swiss 
Tropical Institute, who was not involved in the study. “At the 
same time, it makes sense to move on quickly without shedding 
too many tears, in a ﬁ  eld that is moving much faster than it 
was before the recent injections of money from the Gates 
Foundation, but where it is still impossible to second-guess the 
results of ﬁ  eld trials. This is partly because we do not have any 
good proxy measures of effective immunity in P. falciparum, and 
partly because this is a fertile area for trying out new techniques, 
such as DNA vaccines, where there is still a lot to learn.”
Hill is planning to do further trials that address the important 
question of whether this type of vaccine can prevent the 
symptoms of malaria.  “The next step,” says Hill,  “is to assess 
newer vaccine regimes that employ two viral vectors rather than 
DNA and to study prevention of malaria rather than infection.”
Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, et al. 
(2004) A randomised, controlled, double-blind efﬁ  cacy trial of DNA/
MVA ME-TRAP prime-boost immunisation against malaria infection 
in Gambian adults. DOI: 10.1371/journal.pmed.0010033
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could protect T helper cells, which 
are normally destroyed in the earliest 
stages of infection. They hypothesized 
that early treatment of acute HIV-1 
infection with HAART might boost the 
immune response, allowing it to control 
the HIV-1 infection without the need 
for continuous therapy. “We did not 
know at that time whether the T helper 
cells would be functional,”  explains 
Walker.  “The only way to tell this was to 
stop medications and see if the immune 
response could control the virus.”
To test this hypothesis the researchers 
did an open-label trial of STIs; they 
published data from six months follow-
up in the Nature paper.  “The key ﬁ  nding 
was that we were able to get at least 
transient control of virus in all eight 
persons studied, and in ﬁ  ve of eight the 
viral load was less than 500 copies (very 
low!) at the time of publication,” explains 
Walker. However, at that point they did 
not know how long the protective effects 
would last. 
The ﬁ  rst evidence that protection 
was not complete came two years later 
when Walker’s team reported a case of 
superinfection; one of the patients in the 
original experiment was infected with a 
second strain of HIV, even though the ﬁ  rst 
virus was still well controlled.  “This paper 
was important because it indicated that 
the amount of immunity might be enough 
for the person’s own virus, but might not 
protect against closely related viruses 
circulating in the population,” says Walker.
The PLoS Medicine study adds more 
concern since it shows that although most 
persons can indeed transiently control 
their own virus, they do so for only a 
limited amount of time. “We expanded the 
study to 14 persons, and now have about 
ﬁ  ve years of follow-up on some of the 
patients,” says Walker. “Although we were 
able to use early treatment and structured 
treatment interruption to boost immunity 
and have 11 of 14 patients control their 
virus, most of the persons ultimately 
‘broke through,’ meaning that they had a 
recurrence of viremia.” At the present time 
the researchers do not know what causes 
the loss of viral control.
Walker and colleagues conclude that 
treatment interruptions should probably 
be avoided outside the setting of 
controlled clinical trials, whereas Douek 
goes a step further:  “The study shows 
that even early short-term treatment and 
structured treatment interruptions, using 
current strategies, impart only transient 
beneﬁ  t and are unlikely to serve as a 
reasonable therapeutic option in the 
future.” 
Kaufmann DE, Lichterfeld M, Altfeld M, 
Addo MM, Johnston MN, et al. (2004) 
Limited durability of viral control following 
treated acute HIV infection. DOI: 10.1371/
journal.pmed.0010036
The Quest for a Vaccine 
That Yields Tumor-Killing T cells
DOI: 10.1371/journal.pmed.0010050
The immune system has a remarkable capacity for fending 
off infectious diseases, and it has become clear that these same 
defenses can recognize and destroy cancer cells. In fact, they do 
so on an ongoing basis, and cancer develops only when immune 
surveillance breaks down. Many patients with established tumors 
also mount an immune response against some antigens that are 
speciﬁ  c to, or enriched in, the tumor. This response, however, is 
rarely effective against the disease. 
The idea of enlisting the immune system to ﬁ  ght cancer has 
been around for a long time, and has led to the development of 
various cancer vaccines designed to alert the immune system 
to the presence of a tumor and to induce a response that, 
selectively and potently, will eliminate tumor cells. Vaccines 
include whole tumor extracts or speciﬁ  c proteins and peptides 
that are selectively expressed or enriched in tumors, by 
themselves or with a variety of adjuvants. 
There have been some spectacular successes, in particular 
with immune therapy to malignant melanoma, a tumor type that 
seems naturally to be more immunogenic than others. However, 
even in melanoma, success is usually restricted to a fraction of 
the patients, with no obvious explanation of why the strategy 
works for a particular patient and fails in most others. The 
emphasis has consequently shifted from clinical outcomes to 
monitoring a patient’s immune response. What type of response 
is necessary and sufﬁ  cient to eliminate tumor cells is still unclear, 
but the hope is that understanding the immune response in 
patients that show clinical beneﬁ  t will answer that question. 
Peter Lee and colleagues used state-of-the art technology 
to dissect the endogenous immune response to vaccination 
with heteroclitic melanoma peptides, i.e., melanoma-associated 
peptides that have been engineered to elicit a stronger immune 
response. They focused on cytotoxic T lymphocytes (CTLs), and 
compared CTL clones 
from four melanoma 
patients who had 
vaccine-induced T cell 
responses and two 
melanoma patients 
with spontaneous 
anti-tumor T cell 
responses. The 
researchers analyzed 
several hundred CTL 
clones (to get a sense 
for the complexity 
of the responses in 
individual patients) for 
T cell receptor variable 
chain beta expression, 
recognition efﬁ  ciency, 
and ability to lyse 
target melanoma cells. Most T cells isolated from vaccinated 
patients were poor at tumor cell lysis compared with T cells from 
endogenous responses to cancer. 
The authors suggest that the high doses of peptides 
administered in vaccinations and the increased binding 
capacity of heteroclitic peptides to major histocompatibility 
complex molecules—the very quality that makes them more 
immunogenic—induce many T cells with low recognition 
efﬁ  ciency for the native peptides they encounter on the tumor 
cells. Their ﬁ  ndings also bring into question the ability to 
deduce the recognition efﬁ  ciency and tumor reactivity of T cell 
responses from ELISPOT and tetramer staining assays—the two 
standard measures of T cell responses to vaccines—which has 
implications for rational vaccine design in general.
Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, et 
al. (2004) Diversity and recognition efﬁ  ciency of T cell responses to 
cancer. DOI: 10.1371/journal.pmed.0010028 
DOI: 10.1371/journal.pmed.0010050.g001
Melanoma—a prime target of cancer 
vaccines (Photo: Timothy Triche, 
National Cancer Institute)
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Resistin Response to Inﬂ  ammation
DOI: 10.1371/journal.pmed.0010049
Obesity, in particular visceral adiposity, is positively correlated 
with insulin resistance and type 2 diabetes. Although the 
link is well established in humans and in rodent models, the 
mechanisms involved in obesity-related insulin resistance are not 
clear. One possibility is that hormones secreted by adipocytes 
compromise peripheral insulin sensitivity, and a number of 
candidates for such adipocyte signals have been identiﬁ  ed. One 
of them, resistin, was discovered a few years ago by Mitchell 
Lazar and colleagues, who showed that the protein is expressed 
by mouse adipocytes and regulated by a group of anti-diabetic 
drugs called thiazolidinediones. Several lines of evidence from 
functional studies in rodents suggested that resistin could be the 
missing mechanistic link between obesity and diabetes. 
The human homolog of resistin has subsequently been 
under intense investigation, but initial studies revealed more 
differences than similarities between the human and rodent 
proteins: human resistin is mostly expressed in macrophages, 
not in adipocytes, and its serum levels do not correlate as 
clearly with obesity, insulin resistance, or diabetes. Similarly, 
genetic association studies between allelic variants of the 
resistin gene and metabolic abnormalities have so far been 
inconclusive. These results prompted some of the scientists in 
the ﬁ  eld who had jumped on the resistin bandwagon after the 
initial results in rodents to jump off again. Others, including the 
resistin discoverers, continue their quest to uncover resistin’s 
role in humans, and have started to think outside the framework 
deﬁ  ned by the mouse data. 
Starting with the role of macrophages in inﬂ  ammation and 
encouraged by the fact that obesity and insulin resistance are 
associated with markers of systemic inﬂ  ammation, Lazar and 
colleagues examined the resistin response to inﬂ  ammatory 
stimulators. As they report in this issue, resistin production in 
macrophages and serum levels in patients are signiﬁ  cantly 
increased by these stimulators. This response can be blocked by 
the thiazolidinedione rosiglitazone and by aspirin, two drugs that 
have dual anti-inﬂ  ammatory and insulin-sensitizing actions and 
antagonize the immune regulator NF-kappaB. The researchers go 
on to show that activation of NF-kappaB is sufﬁ  cient to induce 
resistin expression. And NF-kappaB is necessary for the resistin 
response to inﬂ  ammatory stimuli. 
Lazar and colleagues now view obesity as a state of 
chronic inﬂ  ammation and speculate that in obese individuals 
inﬂ  ammatory cytokines lead to elevated production of resistin 
by macrophages and elevated serum resistin levels, which in turn 
contribute to insulin resistance and diabetes. This is consistent 
with some studies that have found higher resistin levels in obese 
individuals and patients with insulin resistance and/or diabetes, 
but not all studies have found such differences. 
Jeffrey Flier, an obesity researcher who was not involved in 
the study, calls the article “an excellent and timely paper that 
demonstrates the fact that inﬂ  ammatory pathways induce 
resistin expression and levels in human monocytes ex vivo, 
and in intact humans. The work appears to provide a novel link 
between inﬂ  ammation and insulin resistance, through monocyte 
derived resistin.” He points out, however, that “several other 
factors also appear to contribute directly to insulin resistance 
in inﬂ  ammation (e.g., cytokines themselves, without invoking 
resistin) so the full biologic implications of the high resistin levels 
for insulin resistance in humans cannot be determined from this 
study.” Resistin, it seems, continues to resist easy interpretations. 
Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, et al. (2004) 
An inﬂ  ammatory cascade leading to hyperresistinemia in humans. 
DOI: 10.1371/journal.pmed.0010045
DOI: 10.1371/journal.pmed.0010049.g001
Connections between obesity and inﬂ  ammation 
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